Medicines Discovery Catapult and Astral Systems secure £1.54m to develop the UK’s radiopharmaceutical lab of the future

Funding will help lay the foundations to make UK radiopharmaceutical production faster, more consistent and ready for rising demand

Medicines Discovery Catapult (MDC) and Astral Systems have been awarded £1.54m from Innovate UK to develop digital and automated laboratory processes that will support the production of next-generation radiopharmaceuticals.

Radiopharmaceuticals can diagnose and treat disease, with game-changing potential for cancer patients.

More than 700,000 NHS procedures rely on them each year ... and demand will rise as new therapies reach the clinic.

Radiopharmaceuticals contain a decaying radionuclide, so they must be made and delivered quickly to stay potent.

Any delay can compromise effectiveness and could cost lives.

Laboratory steps in radiopharmaceutical production are often managed separately, with disconnected systems, manual records and handovers.

With rapidly decaying materials, this raises the risk of errors and reduces efficiency and reliability. Modernising these processes will be essential as demand grows.

Medicines Discovery Catapult and Astral Systems secure £1.54m to develop the UK’s radiopharmaceutical lab of the future

Combining MDC’s radiopharmaceutical expertise with Astral Systems’ compact multi-state fusion devices and engineering capabilities, the partners will build the digital infrastructure for the lab of the future: a single, integrated, automated workflow with efficient data recording and transfer between steps.

It will also include virtual digital avatars, computer models that let scientists test and optimise processes before committing laboratory time.

Using Copper-64 and Copper-67 as pilot radionuclides, an emerging pair for diagnostic imaging and targeted therapy, the project will develop approaches that can be adapted to other radionuclides and transferred across laboratories.

This connected, data-driven framework will make production more efficient, reproducible and scalable, strengthening the UK’s ability to turn radiopharmaceutical research into clinically available medicines and speeding patient access.

Dr Mike Strange, CEO, Medicines Discovery Catapult, said: “The UK has world-class science in radiopharmaceuticals, but it needs the development and manufacturing capability to match if we are to realise the economic and health benefits of this fast-growing field."


"This project is an important step towards ensuring the digital infrastructure is in place to support the next generation of radiopharmaceutical development in the UK and help bring new treatments closer to patients.”


Talmon Firestone, CEO, Astral Systems, added: “Isotopes decay constantly, so every step between the lab and the patient matters."

"This project brings those steps together into one automated, digital workflow, giving researchers more reliable data and the UK a firmer base for the treatments that follow.”

You may also like